KYTX · XBRL financial data

Kyverna Therapeutics financial statements, every quarter

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (KYTX's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	22,476	27,321	29,193	33,483*	37,433	35,816	30,457	30,014*	30,073	24,788
General and administrative	6,882	6,114	9,577	7,558*	9,975	8,594	8,270	9,268*	11,294	14,768
Total operating expenses	29,358	33,435	38,770	41,041*	47,408	44,410	38,727	39,282*	41,367	39,556
Operating income (loss)	(29,358)	(33,435)	(38,770)	(41,041)*	(47,408)	(44,410)	(38,727)	(39,282)*	(41,367)	(39,556)
Interest income	2,735	4,694	4,355	3,575*	2,825	2,364	2,000	1,905*	2,327	1,929
Interest expense	44	39	32	27*	25	14	7	444*	667	674
Other income (expense)	(26)	(23)	(45)	4*	(27)	(21)	(53)	17*	(21)	(18)
Income tax expense (benefit)	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(26,693)	(28,803)	(34,492)	(37,489)*	(44,635)	(42,081)	(36,787)	(37,804)*	(39,728)	(38,319)
Earnings per share, basic USD per share	(1.12)	(0.67)	(0.80)	(0.87)*	(1.03)	(0.97)	(0.85)	(0.80)*	(0.66)	(0.63)
Earnings per share, diluted USD per share	(1.12)	(0.67)	(0.80)	(0.87)*	(1.03)	(0.97)	(0.85)	(0.80)*	(0.66)	(0.63)
Weighted average shares, basic thousands of shares	23,754	43,126	43,156	43,196*	43,216	43,225	43,415	47,150*	60,434	60,897
Weighted average shares, diluted thousands of shares	23,754	43,126	43,156	43,196*	43,216	43,225	43,415	47,150*	60,434	60,897

Balance sheet

CSV

Fiscal quarters (KYTX's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	224,287	131,618	104,663	96,621	56,865	53,440	34,164	124,093	32,194	31,806
Marketable securities	145,507	214,619	216,924	189,358	185,784	158,237	136,974	155,160	204,252	167,621
Prepaid and other current assets	5,694	2,586	3,787	4,622	5,002	2,650	3,787	3,700	5,280	7,115
Total current assets	375,488	348,823	325,374	290,601	247,651	214,327	174,925	282,953	241,726	206,542
Property and equipment, net	2,714	3,366	3,151	3,347	2,436	2,162	1,793	1,546	1,343	1,326
Right-of-use asset	8,486	7,825	7,153	6,468	5,764	5,049	4,317	3,568	8,192	7,848
Total assets	389,984	363,116	339,196	304,645	260,655	226,508	187,156	293,826	257,024	219,823
Accounts payable	7,451	4,861	9,932	4,624	8,472	9,917	3,016	5,306	11,603	2,933
Total current liabilities	21,865	23,478	30,985	33,756	33,292	39,789	33,871	36,487	29,674	22,802
Long-term debt	—	—	—	—	—	—	—	24,743	—	24,883
Lease liability, non-current	6,461	5,722	4,968	4,160	3,280	2,316	1,331	320	6,958	6,589
Total liabilities	28,993	29,607	36,486	38,058	36,645	42,131	35,210	61,550	61,444	54,274
Accumulated deficit	(162,736)	(191,539)	(226,031)	(263,520)	(308,155)	(350,236)	(387,023)	(424,827)	(464,555)	(502,874)
Total stockholders' equity	360,991	333,509	302,710	266,587	224,010	184,377	151,946	232,276	195,580	165,549
Total liabilities and equity	389,984	363,116	339,196	304,645	260,655	226,508	187,156	293,826	257,024	219,823
Common shares outstanding (cover page) thousands of shares	43,115	43,147	43,172	43,215	43,219	43,246	43,796	60,440	60,795	61,843

Cash flows

CSV

Fiscal quarters (KYTX's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(26,693)	(28,803)	(34,492)	(37,489)*	(44,635)	(42,081)	(36,787)	(37,804)*	(39,728)	(38,319)
Stock-based compensation	2,278	1,284*	3,413*	1,382*	2,161	2,518*	2,699*	2,702*	3,171	3,507*
Depreciation and amortization	482	530*	558*	563*	501	515*	415*	368*	351	434*
Net cash from operating activities	(25,525)	(24,175)*	(27,489)*	(37,061)*	(44,915)	(31,949)*	(43,321)*	(33,527)*	(41,597)	(40,306)*
Purchases of property and equipment	543	1,028*	102*	532*	0	4*	2*	(1)*	—	—
Net cash from investing activities	(122,879)	(67,921)*	676*	29,222*	5,578	29,167*	22,557*	(17,287)*	(50,201)	36,130*
Proceeds from issuing common stock	—	—	—	year only	—	—	—	year only	—	—
Net cash from financing activities	338,049	(569)*	(152)*	(215)*	(414)	(649)*	1,488*	140,743*	(101)	3,788*
Net change in cash	189,645	(92,665)*	(26,965)*	(8,054)*	(39,751)	(3,431)*	(19,276)*	89,929*	(91,899)	(388)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Kyverna Therapeutics	31,806	not reported	(40,306)*	61.8M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	17,528	593	(10,477)*	10.2M	1.1 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 7, 2026, 1:23 AM ET. The filing on SEC.gov is the record.